<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Seven adult patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)-related secondary <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) were treated with total body irradiation (TBI), <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (Ara-C) and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY), followed by unrelated human leucocyte antigen (HLA)-mismatched cord blood transplantation (CBT) </plain></SENT>
<SENT sid="1" pm="."><plain>Granulocyte colony-stimulating factor (G-CSF) was infused continuously from 12 h before until the end of Ara-C therapy to enhance the antileukaemia effect of Ara-C </plain></SENT>
<SENT sid="2" pm="."><plain>Five patients are alive and free of disease at 7-31 months after transplantation </plain></SENT>
<SENT sid="3" pm="."><plain>These preliminary results suggest that adult <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-related <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> patients without suitable related or unrelated bone marrow donors should be considered as candidates for CBT </plain></SENT>
</text></document>